Zeitschrift für Gastroenterologie

LinksSchließen

Referenz

Hecht JR, Dakhil SR. et al.
SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology 2013;
31 (Suppl. 04) 454-454

Bibliographische Angaben herunterladen

Suchen in: